Approximately 70% of individuals diagnosed with Major Depressive Disorder (MDD) experience anhedonia, the progressive, pervasive loss of the capacity for pleasure, motivation, and connection that researchers now recognise as one of the most clinically significant and most persistently undertreated features of mood disorders worldwide (Serretti, 2023). In Bipolar Disorder (BD), the figure reaches approximately 52%, with anhedonic symptoms frequently persisting even during periods of apparent clinical stability, when other depressive symptoms have remitted (Whitton & Pizzagalli, 2022). These are not minor or incidental findings. They point toward a symptom that sits at the very heart of mood disorder pathology, one that shapes illness severity, predicts treatment resistance, and independently elevates the risk of suicide, yet continues to be routinely overlooked in favour of targeting low mood alone. For millions of people living with mood disorders, anhedonia is not an occasional bad day. It is the defining feature…